
TVGN Stock Forecast & Price Target
TVGN Analyst Ratings
Bulls say
Tevogen Bio Holdings Inc. has demonstrated a strong potential for its investigational therapy, TVGN 489, in recent clinical trials, showcasing rapid viral elimination and sustained immune cell persistence along with an excellent safety profile. The therapy notably produced faster and more consistent symptom resolution in high-risk patients, including a significant portion of immunocompromised individuals, when compared to standard care. These positive clinical outcomes emphasize the efficacy of Tevogen's unique ExacTcell platform in treating infectious diseases, which may contribute to a favorable long-term outlook for the company.
Bears say
Tevogen Bio Holdings faces a challenging landscape due to the limitations of traditional immunotherapy approaches that focus on single viral proteins, especially in the context of rapidly mutating viruses and emerging variants like XFG. This indicates a potential gap in their therapeutic efficacy, which could hinder the company's ability to compete in a dynamic market. Furthermore, the reliance on a narrow treatment strategy raises concerns regarding the long-term sustainability and commercial viability of Tevogen’s product pipeline.
This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
TVGN Analyst Forecast & Price Prediction
Start investing in TVGN
Order type
Buy in
Order amount
Est. shares
0 shares